keyword
MENU ▼
Read by QxMD icon Read
search

Macular edema anti-VEGF

keyword
https://www.readbyqxmd.com/read/29784048/a-meta-analysis-of-the-effect-of-a-dexamethasone-intravitreal-implant-versus-intravitreal-anti-vascular-endothelial-growth-factor-treatment-for-diabetic-macular-edema
#1
Ye He, Xin-Jun Ren, Bo-Jie Hu, Wai-Ching Lam, Xiao-Rong Li
BACKGROUND: This meta-analysis evaluated the effectiveness and safety of dexamethasone (DEX) implant and intravitreal anti-vascular endothelial growth factor (VEGF) treatment for diabetic macular edema (DME). METHODS: The PubMed, Embase, clinicaltrials.gov website and Cochrane Library databases were comprehensively searched for studies comparing DEX implant with anti-VEGF in patients with DME. Best-corrected visual acuity (BCVA), central subfield thickness (CST) and adverse events were extracted from the final eligible studies...
May 21, 2018: BMC Ophthalmology
https://www.readbyqxmd.com/read/29771880/-anti-vegf-therapy-for-diabetic-macular-edema-from-theory-to-clinical-practice
#2
A Zh Fursova, N V Chubar, M S Tarasov, I F Niculich, M A Vasilyeva, O G Gusarevich
PURPOSE: To evaluate clinical effectiveness of aflibercept therapy for patients with diabetic macular edema (DME) - both naïve to the drug and unresponsive to previous anti-VEGF treatment. MATERIAL AND METHODS: The study included 127 patients (127 eyes) divided into two groups. The first group consisted of 100 primary DME patients (100 eyes) with mean age of 68.48±2.56 years and average disease duration of 12.50±7.85 years. The second group comprised 27 patients (27 eyes) with resistant macular edema who had received three or more 0...
2018: Vestnik Oftalmologii
https://www.readbyqxmd.com/read/29744040/recent-advances-in-understanding-and-managing-retinal-vein-occlusions
#3
REVIEW
Daniel D Esmaili, David S Boyer
Retinal vein occlusions are the second most common form of retinal vascular disease. Previously, laser treatment for branch retinal vein occlusion and intravitreal triamcinolone acetonide for central retinal vein occlusion were the standard of care. Recent studies have demonstrated that anti-vascular endothelial growth factor (anti-VEGF) agents have a superior safety and efficacy profile for the treatment of both branch and central retinal vein occlusions. The use of wide-field fluorescein angiography has also allowed better visualization of the retinal periphery...
2018: F1000Research
https://www.readbyqxmd.com/read/29730822/shall-we-stay-or-shall-we-switch-continued-anti-vegf-therapy-versus-early-switch-to-dexamethasone-implant-in-refractory-diabetic-macular-edema
#4
Catharina Busch, Dinah Zur, Samantha Fraser-Bell, Inês Laíns, Ana Rita Santos, Marco Lupidi, Carlo Cagini, Pierre-Henry Gabrielle, Aude Couturier, Valérie Mané-Tauty, Ermete Giancipoli, Giuseppe D'Amico Ricci, Zafer Cebeci, Patricio J Rodríguez-Valdés, Voraporn Chaikitmongkol, Atchara Amphornphruet, Isaac Hindi, Kushal Agrawal, Jay Chhablani, Anat Loewenstein, Matias Iglicki, Matus Rehak
AIMS: To compare functional and anatomical outcomes of continued anti-vascular endothelial growth factor (VEGF) therapy versus dexamethasone (DEX) implant in eyes with refractory diabetic macular edema (DME) after three initial anti-VEGF injections in a real-world setting. METHODS: To be included in this retrospective multicenter, case-control study, eyes were required: (1) to present with early refractory DME, as defined by visual acuity (VA) gain ≤ 5 letters or reduction in central subfield thickness (CST) ≤ 20%, after a loading phase of anti-VEGF therapy (three monthly injections) and (2) to treat further with (a) anti-VEGF therapy or (b) DEX implant...
May 5, 2018: Acta Diabetologica
https://www.readbyqxmd.com/read/29719645/intravitreal-injection-of-anti-vascular-endothelial-growth-factor-agents-for-ocular-vascular-diseases-clinical-practice-guideline
#5
Homayoun Nikkhah, Saeed Karimi, Hamid Ahmadieh, Mohsen Azarmina, Majid Abrishami, Hossein Ahoor, Yousef Alizadeh, Hasan Behboudi, Narsis Daftarian, Mohammad Hossein Dehghan, Morteza Entezari, Fereydoun Farrahi, Heshmatollah Ghanbari, Khalil Ghasemi Falavarjani, Mohammad Ali Javadi, Reza Karkhaneh, Siamak Moradian, Masoud Reza Manaviat, Morsal Mehryar, Ramin Nourinia, Mohammad Mehdi Parvaresh, Alireza Ramezani, Alireza Ragati Haghi, Mohammad Riazi-Esfahani, Masoud Soheilian, Mohsen Shahsavari, Hossein-Ali Shahriari, Zhale Rajavi, Sare Safi, Armin Shirvani, Saeed Rahmani, Hamideh Sabbaghi, Mojgan Pakbin, Bahareh Kheiri, Hossein Ziaei
Purpose: To provide the clinical recommendations for the administration of intravitreal anti-vascular endothelial growth factor (VEGF) drugs especially bavacizumab for ocular vascular diseases including diabetic macular edema, neovascular age-related macular degeneration, myopic choroidal neovascularization, retinal vein occlusion and central serous chorioretinopathy. Methods: Twenty clinical questions were developed by the guideline technical committee. Relevant websites and databases were searched to find out the pertinent clinical practice guidelines to answer the questions...
April 2018: Journal of Ophthalmic & Vision Research
https://www.readbyqxmd.com/read/29684329/vision-outcomes-following-anti-vascular-endothelial-growth-factor-treatment-of-diabetic-macular-edema-in-clinical-practice
#6
Nancy M Holekamp, Joanna Campbell, Arghavan Almony, Herbert Ingraham, Steven Marks, Hitesh Chandwani, Ashley L Cole, Szilárd Kiss
PURPOSE: To determine monitoring and treatment patterns, and vision outcomes in real-world patients initiating anti-vascular endothelial growth factor (anti-VEGF) therapy for diabetic macular edema (DME). DESIGN: Retrospective interventional cohort study. METHODS: SETTING: Electronic medical record analysis of Geisinger Health System data. STUDY POPULATION: 110 patients (121 study eyes) initiating intravitreal ranibizumab or bevacizumab for DME during January 2007‒May 2012, with baseline corrected visual acuity of 20/40‒20/320, and ≥1 ophthalmologist visits during follow-up...
April 20, 2018: American Journal of Ophthalmology
https://www.readbyqxmd.com/read/29683983/fluorescein-angiography-indications-changes-after-optical-coherence-tomography-and-antiangiogenics
#7
Sonia C Labrador-Velandia, María R Sanabria
SIGNIFICANCE: The present study provides quantitative data regarding the change of indications of fluorescein angiography in a tertiary hospital. Exhaustively compiled data over more than 10 years concerning all the angiographic studies including diagnosis, first-visit/follow-up, possible relation with antiangiogenics approval, and optic coherence tomography (OCT) are presented. PURPOSE: The aim of this study was to determine the frequency and indications of fluorescein angiography before and after OCT and anti-vascular endothelial growth factor (anti-VEGF) treatment implantation...
May 2018: Optometry and Vision Science: Official Publication of the American Academy of Optometry
https://www.readbyqxmd.com/read/29662298/anti-vegf-treatment-of-macular-edema-associated-with-retinal-vein-occlusion-patterns-of-use-and-effectiveness-in-clinical-practice-echo-study-report-2
#8
J Michael Jumper, Pravin U Dugel, Sanford Chen, Kevin J Blinder, John G Walt
Purpose: To evaluate the efficacy, safety, and injection frequency of vascular endothelial growth factor (VEGF) antagonists in the treatment of macular edema secondary to retinal vein occlusion (RVO) in clinical practice. Patients and methods: A multicenter retrospective study of the medical records of 165 patients (95 branch RVO, 70 central RVO) treated with at least three anti-VEGF injections in the study eye was conducted. Available data collected for at least 6 months after the first injection included Snellen best-corrected visual acuity (BCVA), central retinal thickness (CRT) by time-domain optical coherence tomography (TD-OCT) or spectral-domain optical coherence tomography (SD-OCT), anti-VEGF injections, other treatments/procedures for RVO, and adverse events...
2018: Clinical Ophthalmology
https://www.readbyqxmd.com/read/29621780/short-term-results-of-intravitreal-triamcinolone-acetonide-combined-with-cataract-surgery-for-diabetic-macular-edema-in-japan-in-the-era-of-anti-vascular-endothelial-growth-factor-therapy
#9
Takayasu Nunome, Masahiko Sugimoto, Mineo Kondo, Chikako Suto
PURPOSE: To evaluate the effectiveness of an intravitreal triamcinolone acetonide injection (IVTA) combined with cataract surgery for diabetic macular edema (DME) resistant to anti-vascular endothelial growth factor (anti-VEGF) therapy. PROCEDURE: IVTA combined with cataract surgery was performed on 29 eyes of patients with DME (aged 70.5 ± 6.2 years) who were refractive to anti-VEGF treatments. The visual acuity, central retinal thickness (CRT), and the central retinal sensitivity were assessed at 1, 4, 12, and 24 weeks after the treatment...
April 5, 2018: Ophthalmologica. Journal International D'ophtalmologie
https://www.readbyqxmd.com/read/29611471/peroxisome-proliferated-activated-receptors-ppars-opportunities-and-challenges-for-ocular-therapy
#10
Prachi Khatol, Shivani Saraf, Ankit Jain
Peroxisome proliferator-activated receptors (PPARs) are nuclear transcription factors. They exist in three isoforms (PPAR-α, PPAR-β/δ, and PPAR-Υ) in humans, but mainly PPAR-Υ, and they are expressed in retinal epithelial pigment. PPARs are involved in mediating numerous pathological implications in eye such as diabetic retinopathy (DR), choroidal neovascularization (CNV), glaucoma, diabetic macular edema, and other retinal diseases. Peroxisome proliferator-activated receptors are key players in various biological pathways like lipid degeneration, immune regulation, and reactive oxygen species regulation, regulation of vascular endothelial growth factor, matrixmetalloproteinase-9, and docosahexaenoic acid pathway...
2018: Critical Reviews in Therapeutic Drug Carrier Systems
https://www.readbyqxmd.com/read/29600177/intravitreal-anti-vegf-agents-oral-glucocorticoids-and-laser-photocoagulation-combination-therapy-for-macular-edema-secondary-to-retinal-vein-occlusion-preliminary-report
#11
Xiao-Xiao Feng, Cheng Li, Wan-Wen Shao, Yong-Guang Yuan, Xiao-Bing Qian, Qi-Shan Zheng, Yu-Jie Li, Qian-Ying Gao
AIM: To evaluate the efficacy and safety of combined anti-vascular endothelial growth factor (VEGF) agents, oral glucocorticoid, and laser photocoagulation therapy for macular edema (ME) secondary to retinal vein occlusion (RVO). METHODS: This study included 16 eyes of 16 patients with RVO-associated ME. Patients were initially treated with oral prednisone and an intravitreal anti-VEGF agent. Two weeks later, patients underwent standard laser photocoagulation. Best-corrected visual acuity (BCVA), central retinal thickness (CRT), and retinal vessel oxygenation were examined over 12mo...
2018: International Journal of Ophthalmology
https://www.readbyqxmd.com/read/29566105/overview-of-systematic-reviews-and-meta-analyses-on-systemic-adverse-events-associated-with-intravitreal-anti-vascular-endothelial-growth-factor-medication-use
#12
Marie Thulliez, Denis Angoulvant, Pierre-Jean Pisella, Theodora Bejan-Angoulvant
Importance: The systemic safety of intravitreal anti-vascular endothelial growth factor (anti-VEGF) medications is still a matter of debate. Objective: This overview of systematic reviews evaluates systemic adverse events associated with intravitreal anti-VEGF treatments in patients with neovascular age-related macular degeneration, diabetic macular edema, or retinal vein occlusion. Design, Evidence, and Reporting: This systematic search of PubMed and the Cochrane Central Register of Controlled Trials database includes meta-analyses and systematic reviews...
March 22, 2018: JAMA Ophthalmology
https://www.readbyqxmd.com/read/29550187/effects-of-crocin-on-diabetic-maculopathy-a-placebo-controlled-randomized-clinical-trial
#13
Samaneh Sepahi, Seyed Ahmad Mohajeri, Seyedeh Maryam Hosseini, Elham Khodaverdi, Nasser Shoeibi, Maral Namdari, Sayyed Abolghasem Sajadi Tabassi
OBJECTIVE: Diabetic macular edema (DME) is one of the most important sight-threatening complications in patients with diabetes. Due to neuroprotective properties, crocin, as the main constituent in saffron, is thought to be useful in the treatment and prevention of diabetic maculopathy. The aim of this trial was to evaluate the effects of crocin as a supplement on reducing inflammation in patients with diabetic maculopathy. DESIGN: Double blind, placebo controlled, phase 2 randomized clinical trial...
March 14, 2018: American Journal of Ophthalmology
https://www.readbyqxmd.com/read/29528861/recent-clinically-relevant-highlights-from-the-diabetic-retinopathy-clinical-research-network
#14
REVIEW
Tracy W Krick, Neil M Bressler
PURPOSE OF REVIEW: To present some recent clinically relevant results from Diabetic Retinopathy Clinical Research (DRCR) Network trials that may guide management of diabetic macular edema (DME) or proliferative diabetic retinopathy (PDR). RECENT FINDINGS: Among eyes with DME and visual acuity 20/50 or worse, aflibercept, on average, had greater improvement in visual acuity over 2 years compared with bevacizumab or ranibizumab. Aflibercept is associated with higher rates of improvements in diabetic retinopathy severity among eyes with PDR and vision-impairing DME at baseline compared with bevacizumab or ranibizumab...
May 2018: Current Opinion in Ophthalmology
https://www.readbyqxmd.com/read/29525602/plasma-vascular-endothelial-growth-factor-concentrations-after-intravitreous-anti-vascular-endothelial-growth-factor-therapy-for-diabetic-macular-edema
#15
Lee M Jampol, Adam R Glassman, Danni Liu, Lloyd Paul Aiello, Neil M Bressler, Elia J Duh, Susan Quaggin, John A Wells, Charles C Wykoff
PURPOSE: To assess systemic vascular endothelial growth factor (VEGF)-A levels after treatment with intravitreous aflibercept, bevacizumab, or ranibizumab. DESIGN: Comparative-effectiveness trial with participants randomly assigned to 2 mg aflibercept, 1.25 mg bevacizumab, or 0.3 mg ranibizumab after a re-treatment algorithm. PARTICIPANTS: Participants with available plasma samples (N = 436). METHODS: Plasma samples were collected before injections at baseline and 4-week, 52-week, and 104-week visits...
March 7, 2018: Ophthalmology
https://www.readbyqxmd.com/read/29522144/aqueous-humor-cytokine-levels-and-anatomic-response-to-intravitreal-ranibizumab-in-diabetic-macular-edema
#16
Roxane J Hillier, Elvis Ojaimi, David T Wong, Michael Y K Mak, Alan R Berger, Radha P Kohly, Peter J Kertes, Farzin Forooghian, Shelley R Boyd, Kenneth Eng, Filiberto Altomare, Louis R Giavedoni, Rosane Nisenbaum, Rajeev H Muni
Importance: Variability in response to anti-vascular endothelial growth factor (VEGF) treatment in diabetic macular edema (DME) remains a significant clinical challenge. Biomarkers could help anticipate responses to anti-VEGF therapy. Objectives: To investigate aqueous humor cytokine level changes in response to intravitreal ranibizumab therapy for the management of DME, and to determine the association between baseline aqueous levels and anatomic response. Design, Setting, and Participants: In this prospective multicenter cohort study, 49 participants with diabetes mellitus complicated by center-involving DME, with a central subfield thickness of 310 μm or greater on spectral-domain optical coherence tomography (SD-OCT), were recruited from December 22, 2011, to June 13, 2013 and statistical analysis were performed from March 1, 2017, to June 1, 2017...
April 1, 2018: JAMA Ophthalmology
https://www.readbyqxmd.com/read/29479906/retinal-nerve-fiber-layer-thickness-in-glaucoma-patients-treated-with-multiple-intravitreal-anti-vegf-bevacizumab-injections
#17
Andrijana Kopić, Dubravka Biuk, Josip Barać, Maja Vinković, Tvrtka Benašić, Vlatko Kopić
Over the past decade, intravitreal injections of anti-VEGF agents have been widely used and intensively developed as a treatment option for many ophthalmological indications. Due to its availability and low cost, the most frequently used anti-VEGF agent is bevacizumab. This type of therapy is often indicated in patients with exudative age-related macular degeneration (ARMD) and diabetic macular edema (DME). If, in addition to these two conditions, patients have a diagnosis of primary open angle glaucoma (POAG), they also present with optic nerve head (ONH) retinal nerve fiber layer (RNFL) thinning...
September 2017: Acta Clinica Croatica
https://www.readbyqxmd.com/read/29476687/comparison-of-monthly-vs-treat-and-extend-regimens-for-individuals-with-macular-edema-who-respond-well-to-anti-vascular-endothelial-growth-factor-medications-secondary-outcomes-from-the-score2-randomized-clinical-trial
#18
Ingrid U Scott, Paul C VanVeldhuisen, Michael S Ip, Barbara A Blodi, Neal L Oden, Michael Altaweel, Daniel M Berinstein
Importance: Comparisons of monthly vs treat-and-extend anti-vascular endothelial growth factor (anti-VEGF) regimens for macular edema from central retinal vein occlusion or hemiretinal vein occlusion is needed. Objective: To compare visual acuity letter score and central subfield thickness outcomes of participants in the Study of Comparative Treatments for Retinal Vein Occlusion 2 (SCORE2) trial who then received either monthly injections or treat-and-extend (TAE) regimens of aflibercept or bevacizumab after a good response at month 6...
April 1, 2018: JAMA Ophthalmology
https://www.readbyqxmd.com/read/29473719/diabetic-macular-edema-current-understanding-pharmacologic-treatment-options-and-developing-therapies
#19
REVIEW
Kevin Miller, Jorge A Fortun
Diabetic retinopathy and diabetic macular edema comprise a major source of visual disability throughout the developed world. The etiology and pathogenesis of macular edema is intricate and multifactorial, in which the hyperglycemic state in diabetes induces a microangiopathy. Through several inflammatory and vasogenic mediators, including vascular endothelial growth factor (VEGF) upregulation and inflammatory cytokines and chemokines, pathologic changes are induced in the vascular endothelium triggering breakdown of the blood retinal barrier, causing extravasation of fluid into the extracellular space and manifesting clinically as macular edema, resulting in visual loss...
January 2018: Asia-Pacific Journal of Ophthalmology
https://www.readbyqxmd.com/read/29468217/ranibizumab-induced-retinal-reperfusion-and-regression-of-neovascularization-in-diabetic-retinopathy-an-angiographic-illustration
#20
Shruti Chandra, Jay Sheth, Giridhar Anantharaman, Mahesh Gopalakrishnan
Purpose: To report regression of neovascularization and reperfusion of ischemic areas of the retina on Wide-field Digital Fluorescein Angiography following anti-vascular endothelial growth factor injections in a patient with active Proliferative Diabetic Retinopathy. Observations: Case report of sixty-one-year-old male patient with proliferative diabetic retinopathy and diabetic macular edema documented on wide field digital fluorescein angiography. The patient was treated with three intravitreal injections of ranibizumab given at monthly intervals...
March 2018: American Journal of Ophthalmology Case Reports
keyword
keyword
36615
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"